论文部分内容阅读
目的：观察烧伤创面抗真菌感染及防治浅部真菌病外用新药复方萘替芬（Ｓ１１２３）的体外抑菌效果和临床疗效。方法：（１）体外检测萘替芬、酮康唑和Ｓ１１２３的最低抑菌浓度，比较３种药物的抗真菌效果；（２）将Ｓ１１２３和对照药品应用于烧伤创面，在治疗前后取创面痂皮进行真菌培养，观察真菌转阴率；（３）观察Ｓ１１２３冷霜治疗某舰艇部队浅部真菌病患者１９２７例的效果。结果：Ｓ１１２３对丝状真菌和酵母菌具有广谱、高效的抑菌作用，对常见的致病真菌——曲霉和念珠菌，其最小抑菌浓度分别为０．１５６，０．６２５μｇ／ｍｌ。临床使用双盲法观察３ｄ真菌感染转阴率达７７．７１％，与对照组比较相差非常显著。对浅部真菌病治疗的有效率为９５．６％。结论：Ｓ１１２３是一种疗效很好的外用抗真菌新药。
Objective: To observe the antimicrobial effect and clinical efficacy of naftifine (S1123), a new anti-fungal infection in the treatment of superficial mycosis and superficial mycosis, in vitro. Methods: (1) The minimum inhibitory concentrations of naftifine, ketoconazole and S1123 were tested in vitro and the antifungal effects of three drugs were compared. (2) S1123 and control drugs were applied to burn wounds before and after treatment Skin fungal culture to observe the fungal negative rate; (3) To observe the effect of S1123 cold cream treatment of 1927 cases of superficial fungal disease in a naval vessel. Results: S1123 had broad-spectrum and high-efficient bacteriostasis against filamentous fungi and yeasts. The minimum inhibitory concentration against S180, Aspergillus and Candida were 0.156 and 0.625 μg / ml, respectively. Double-blind clinical observation of 3d fungal infection rate of negative conversion rate of 77.71%, compared with the control group, a significant difference. The treatment of superficial mycosis effective rate was 95.6%. Conclusion: S1123 is a good topical antifungal agent.